Implied Podcast

Dave Inc. (DAVE) just capped off a brutal week, plunging nearly 23% amid Fed controversy and fears of new banking regulations. The twist? The company just refinanced its debt and analysts argue it has zero exposure to the fees driving the market panic. In this episode, we break down the massive disconnect between Dave’s crashing stock price and its booming 63% revenue growth. Is this a "mistaken identity" sell-off creating a rare discount, or is it dangerous to catch a falling knife in this volatile sector? Dive in to see why the facts might contradict the fear.

Figma, the design powerhouse that nearly merged with Adobe for $20 billion, is now trading around $36—a staggering 75% drop from its $142 post-IPO high. But don't let the price tag fool you. While the stock looks like a "broken IPO," the business is hitting massive milestones, including crossing the $1 billion annual revenue run rate with 38% growth.In this episode of Implied, we peel back the curtain on why a $1.1 billion paper loss is masking a cash-rich company with $1.5 billion on the sidelines. We explore how Figma’s acquisition of the AI startup Weavy is turning the tables on Adobe and why a 131% net dollar retention rate makes this one of the stickiest products in tech history. Is this a valuation trap at 18x sales, or a rare chance to buy a generational leader at a deep discount? Tune in for the full breakdown of Figma’s wild 2026 trajectory.

Abercrombie & Fitch just saw an 18% hole blown in its stock chart, despite reporting record holiday demand. Why the panic? Wall Street is fixating on a new $90 million tariff bill and rising capital expenses, ignoring the brand’s massive turnaround success. In this episode, we break down why "good" isn't good enough for this market anymore and analyze the setup: is this a warning signal for retail margins, or a massive "sell-the-news" overreaction that created a buying opportunity?

Coty shares are seeing ghosts, trading near 52-week lows at $3.06 after being practically cut in half over the last year. Despite a massive $750 million cash injection from selling its Wella stake, Wall Street is terrified by a sudden CEO shakeup and a wider crisis hitting rival Estée Lauder. In this episode, we break down why the market hates the uncertainty—and why they might be missing the massive debt paydown happening behind the scenes. Is this a "falling knife" or a cleaner company trading at rock-bottom multiples? Tune in to find out if this is the end of the line or the ultimate value play.

American International Group just surrendered months of gains, shedding nearly 10% in a bloodbath week after a surprise "reserve strengthening" announcement. Investors are fleeing as fears mount that the insurer’s underwriting models are fundamentally broken and "structural damage" has been done. In this episode of Implied, we break down the critical "Combined Ratio" miss, why the market is having 2008 flashbacks, and the risk of "cockroach theory." Is this a rare chance to buy a blue-chip at book value, or is the bleeding just getting started? Dive in to find out why you shouldn't catch this falling knife just yet.

Regencell Bioscience (RGC) just went from a massive 60% rally to a sudden 20% plunge in less than 24 hours—and there is absolutely zero news to explain it. Despite having a market cap floating around $10 billion, the company has generated effectively no revenue and is trading at a staggering 5,000x book value. In this episode, we break down the dangerous mechanics behind this "roller coaster," the shadow of a DOJ probe, and why this stock is behaving less like an investment and more like a "lottery ticket in a burning building."

SiTime just erased $1 billion in market value in a single session, falling over 10% despite being the heartbeat of modern AI infrastructure. The stock has been a rocket ship—up 56% in the last year—but today it sliced through key technical levels as investors finally questioned its astronomical valuation. Is this a disastrous breakdown, or a rare chance to buy the "Endura" defense play at a discount? In this episode, we analyze whether this massive selloff is just a shakeout of the "tourists" or a warning not to catch a falling knife.

Just 24 hours ago, D-Wave Quantum was flying high on CES 2026 news—but today, the stock crashed nearly 10%. Why? A top executive just unloaded $24 million worth of shares right into the rally. In this episode of Implied, we break down whether this massive insider sale signals a lack of confidence or just a smart cash-out. With an $11 billion valuation on just $3.74 million in quarterly revenue, is the quantum bubble bursting, or will upcoming government contracts save the day? Tune in to find out why you might want to wait before buying this dip.

Axia Energia (formerly Eletrobras) is getting hammered, shedding nearly 10% as its massive rebrand hits a wall. The trigger? A controversial new deal for a green hydrogen plant that investors see as pure cash burn rather than innovation. In this episode, we break down why the market is aggressively rejecting Axia’s pivot from boring utility dividends to high-stakes tech, and whether this selloff is a disastrous "false start"… or a rare chance to buy a future energy giant at a discount.

Nike just face-planted with a massive 10% drop, despite technically beating earnings estimates. Why the bloodbath? The "turnaround" just hit a reality check: crushing tariffs have destroyed margins, and sales in China are in freefall. In this episode of Implied, we look past the headline numbers to explain why CEO Elliott Hill’s "middle innings" narrative isn't sticking. Is the sales jump in North America a sign of life, or is this stock a "falling knife" that you shouldn't touch yet? Tune in for the full breakdown.

Insmed’s 200% rally just hit a brutal wall. The stock crashed 17% after its star drug, Brinsupri, failed a key Phase 2 study—shattering the thesis that it could be a "Swiss Army Knife" for inflammation. Even a surprise acquisition announcement couldn't distract Wall Street from the flop. In this episode, we break down the failed "misdirection" play and analyze the wreckage: Is this a disastrous signal for the rest of the pipeline, or just an overreaction to "spilled gravy" while the core billion-dollar business remains safe?

GE Vernova just baffled Wall Street with a massive 10% crash on the exact same day it received a "Strong Buy" upgrade from Evercore ISI. Why did good news trigger a liquidation event? The answer lies in a ticking clock: the critical December 31st deadline for the trouble-plagued Vineyard Wind project. In this episode, we break down why investors are fleeing the offshore wind risk, whether the market is ignoring the massive backlog in Data Center Power, and if this selloff is a red flag or the ultimate contrarian buying opportunity.

Affirm just pulled off the market’s wildest reversal of the month. What started as a 6% pre-market drop on news of a massive $750 million debt offering turned into a 12% surge by the closing bell. Why? Because Wall Street realized this wasn't a desperate cash grab—it was a calculated power move. In this episode, we break down how Affirm is using cheap debt to fund a $300 million stock buyback, forcing shorts to cover and betting big on their own holiday performance. Is this a masterclass in financial engineering, or is Affirm getting too expensive in a fragile economy? Tune in to find out why the script just flipped for AFRM.

Applied Digital just erased nearly 20% of its value in a brutal two-day selloff—despite having zero bad news of its own. The culprit? "Sector guilt." After Fermi Inc’s crash and soft signals from Oracle, investors are panic-selling the AI infrastructure trade. In this episode, we break down whether this is a reckless "baby out with the bathwater" moment given APLD's massive CoreWeave contract, or if high debt and a nosebleed 45x valuation mean the pain is just beginning. Dive in to see if this is a discount or a trap.

Fermi Inc just suffered a catastrophic 34% crash, closing at $10 just two months after its hot IPO. The catalyst? The mysterious "Anchor Tenant" behind its massive Project Matador suddenly walked away, terminating a vital $150 million funding deal. In this episode, we break down why the "trust me" phase is officially over, whether the company is now just a land developer with no customers, or if this massive drop creates a rare entry point for their valuable energy permits. Tune in to decide if Fermi is a bargain or a falling knife.

Robinhood just hit a massive speed bump, crashing 9% after an incredible 270% rally in 2025. Investors panicked over a sharp drop in trading volumes—equity down 37%—and a decline in funded customers. But is the retail army actually retreating, or is this just a "hangover" after a record-breaking October? We break down the technical reality behind the user drop, the valuation risks, and whether this pullback is a danger signal or a misunderstood entry point.

Pan American Silver just ripped 11% higher in a single session, capitalizing on silver smashing through an all-time high of $60 per ounce. Despite a slight earnings miss, Wall Street is all-in on the miner’s record free cash flow and the massive payoff from its Yamana Gold acquisition. In this episode, we break down why the "poor man's gold" has suddenly become the rich man's trade, and whether buying this breakout is a brilliant move or reckless gambling just hours before a binary Federal Reserve decision.

Unilever just finalized its "Great Ice Cream Divorce," but the new standalone company (Ticker: MAG) stumbled right out of the gate, opening below its €12.80 reference price. The market gave the Ben & Jerry’s owner a chilly reception, valuing the spin-off at a lackluster €10 billion as index funds rush to sell. In this episode, we break down the mechanics of the 8-for-9 share consolidation, why Unilever investors are suffering from separation anxiety, and whether this messy "melt" is a warning sign—or a rare contrarian opportunity to scoop up the world’s biggest ice cream maker at a bargain.

Pure Storage just erased a quarter of its value overnight, crashing 25% despite beating revenue estimates and hitting earnings targets. Why the panic? The market just snapped out of its "AI trance." Investors realized they were paying software premiums (50x earnings) for hardware margins, creating a massive valuation disconnect compared to rivals like Dell. In this episode, we break down why Wall Street punished "good" numbers and whether this emotional selloff is a red flag or the "sale of the year."

Zscaler just delivered a CEO’s dream: a classic "beat and raise" report with 26% revenue growth and increased annual guidance. The market’s reaction? A brutal 13% selloff. In this episode of Implied, we dissect the "high expectations hangover" that turned a stellar report into a bloodbath. With the stock trading at 16x sales but printing cash with unheard-of 52% margins, is this a harsh valuation reality check or a massive buying opportunity? Dive in to understand the irrationality behind the drop.

Burlington Stores just got hammered, dropping nearly 12% despite crushing profit estimates and raising full-year guidance. The culprit? A meager 1% sales growth and an old nemesis: unseasonably warm weather. While competitors like TJX and Ross are hitting highs, investors are punishing Burlington for relying too heavily on coat season. In this episode, we break down why this "good news" became a disaster, and whether this selloff is a massive overreaction to a warm October or a sign that Burlington is losing the retail war.

Novo Nordisk just hit a brick wall, dropping nearly 10% after its highly anticipated Alzheimer’s trial failed to deliver results. The stock has now lost half its value this year, a brutal reversal just days after rival Eli Lilly crossed the historic $1 trillion mark. Is the weight-loss king dead, or is this a massive market overreaction? In this episode, we break down the failed "Evoke" data, the Zepbound takeover, and why Novo is officially the underdog in the $150 billion obesity war.

Billion To One (BLLN) just delivered a massive 15% daily surge, effectively doubling its stock price just weeks after its IPO. Why is Wall Street obsessing over this new biotech player? It comes down to "Molecular Counting"—proprietary tech claiming to be 1,000x more sensitive than standard PCR—and a massive $500 million cash war chest.

Affirm stock just shed 14% in a single week, leaving investors baffled. The twist? The company actually crushed earnings, posting 34% revenue growth and a surprise profit. The problem isn't Affirm—it’s Klarna. Wall Street is terrified that Klarna’s reliance on "junk fees" will trigger a regulatory crackdown that drags the whole sector down.

Chipotle’s stock has been cut in half, crashing 50% over the last 12 months as the "growth at any cost" era comes to a screeching halt. Why the massive freefall? Beyond the brutal 0.3% same-store sales growth, a new class-action lawsuit regarding "inconsistent portion sizes" has rattled investors, confirming that fixing the viral complaints is destroying margins.

LandBridge just delivered massive numbers—revenue up 78% and tripled net income—yet the stock nose-dived 15%. Why? Because the people running the show just decided to sell. In a classic "selling shareholder" move, insiders dumped $175 million in stock, signaling they think the price has peaked while the company itself gets zero proceeds.

Remitly's stock is in a "total bloodbath," hitting a new 52-week low despite posting 21% customer growth and raising its full-year guidance. What went wrong? The company just delivered a 78% gut-punch on its earnings-per-share, missing Wall Street's expectations by a mile.

Duolingo just reported a mind-blowing 680% earnings beat... and the stock immediately crashed 25%. It’s the paradox of the year. Why? Because management followed up their best quarter ever by slashing Q4 guidance, telling investors they are intentionally "limiting monetization" to focus on the product. Wall Street wanted profits; Duolingo chose to go to war with AI.

Oracle’s stock just crashed 25% in the last month, despite revealing a staggering $455 billion cloud backlog—more than double Amazon’s. So why the bloodbath? Because Wall Street isn't seeing a payday; they're seeing an invoice. Oracle is now sitting on $111 billion in debt, racing to build the data centers required to fulfill those AI deals.

Nubank just hit a milestone that sounds impossible: it now banks over 60% of the entire adult population of Brazil. It’s not a fintech startup anymore; it’s the bank. With a stunning 80-cent cost-per-customer (vs. $15 for rivals) and 42% profit growth, the stock (NU) is ripping to all-time highs. But here's the catch: it’s all happening just 48 hours before their Q3 earnings report.

First Clover Health, now Oscar. The "tech-first" insurance model is getting hammered, and Oscar Health just became the latest casualty, plunging 15% in a single day. In this episode, we break down why a 28% growth in new members means nothing when you’re losing more money on all of them.

Welcome to Implied! On this episode, we break down the massive, nearly 8% plunge in Block's stock ($SQ) after their Q3 earnings report.What exactly sent a payments giant tumbling? It's the classic Wall Street dilemma: the good news wasn't good enough, and the market is punishing the company for one key, avoidable mistake.

DoorDash just suffered its biggest one-day drop ever—down 17%—despite posting 27% revenue growth. Why? Because the company’s spending big on AI, logistics, and global expansion, betting on long-term dominance over short-term profits.

Pinterest just had its worst day in years, crashing nearly 20% after weak holiday guidance and a chilling signal for the ad market. Despite hitting 600 million users, investors are losing patience as ad revenue per user falls and spending stays high. Can Pinterest’s AI-shopping bet turn it around, or is this a warning that growth without profits won’t cut it anymore? Dive in to find out what’s implied behind the drop.

Hertz just shocked Wall Street with a 37% stock surge after posting an unexpected profit — its first real comeback since the EV meltdown and bankruptcy saga.

Kimberly-Clark just shocked Wall Street with a $48.7 billion move to buy Kenvue — the Tylenol and Band-Aid company. It’s a bold bet to pivot from tissues and diapers into consumer health, as the Huggies maker chases higher margins and faster growth.

Pensana’s stock jumped after reports that the U.S. Export-Import Bank may fund up to $160 million for its Longonjo rare earth project in Angola — a potential breakthrough in the West’s race to build a China-free “mine-to-magnet” supply chain. But can government backing fix the company’s cash crunch and stalled UK refinery plans?

Chipotle’s red-hot growth just cooled off fast. The stock plunged double digits after the company slashed its full-year forecast for the third time this year. Even higher-income customers are cutting back, same-store sales are barely up, and inflation’s squeezing margins.

Fiserv just suffered its worst stock drop ever — a staggering 40% plunge in one day. The payments powerhouse behind billions of transactions shocked Wall Street with a brutal earnings miss, slashed guidance, and a leadership shake-up that left analysts “speechless.”

Netflix just gave Wall Street a fright — the stock crashed more than 10% after an unexpected $600 million tax hit from Brazil crushed margins and wiped out billions in market value.

Cleveland-Cliffs just shocked Wall Street — the stock surged nearly 20% after announcing plans to move beyond steel and into rare-earth mining. In this episode, Rojo breaks down how this bold pivot could transform the company from “old steel” to “strategic materials,” why tariffs gave it a boost, and whether this rally is real or just hype.

Kenvue’s nightmare just got worse — the stock’s down 13% as thousands sue over baby powder in the U.K. and the White House eyes a review linking Tylenol to autism risk. With lawsuits piling up, an interim CEO, layoffs, and activist investors circling, the once “safe” consumer-health giant looks anything but steady.

Critical Metals Corp. ($CRML) is the market’s latest roller coaster — soaring on talk of a potential U.S. government stake, then plunging back under $23 as the hype cools.

Critical Metals Corp. just became the hottest small-cap in the market — with rumors that the U.S. government might take a stake in its massive Greenland rare-earth project. Could this be a national-security win or just another speculative frenzy?

Wynn Resorts just can’t catch a break — weak Macau results, a $5.5M fine, and an abandoned New York casino bid have investors spooked. But billionaire Tilman Fertitta is buying big, quietly building a 12% stake. Is he seeing a turnaround no one else does?

Qualcomm’s walking a tightrope — China’s antitrust regulators say the chip giant skipped approval on its Autotalks acquisition, sending shares down 7%. At the same time, Qualcomm’s pushing hard into AI PCs, automotive, and data centers with bold bets on Arduino and Alphawave Semi. But can they reinvent themselves while lawsuits and regulators close in? Find out why this could be Qualcomm’s most pivotal moment yet.

Venture Global’s stock just crashed over 20% after losing a billion-dollar arbitration case to BP — and that’s only the beginning. This episode breaks down how a single legal defeat could trigger a domino effect of claims, derail financing for its next mega-project, and ignite a full-blown credibility crisis in the U.S. LNG industry.

Grupo Financiero Galicia just soared over 21% in a single day — and it’s not hype. Investors are finally buying into its bold bet: integrating HSBC Argentina while scaling its fintech arm, Naranja X. Can Galicia really pull off Argentina’s most ambitious banking merger and dominate both traditional and digital finance? Let’s break down why Wall Street suddenly believes it can.

Ferrari just shocked Wall Street — raising its 2025 outlook while cutting its electric-vehicle targets in half. Investors wanted speed; Ferrari chose soul. In this episode of Implied, we break down why the stock plunged 15%, what the shift means for the brand’s legendary identity, and how the new Elettrica could decide Ferrari’s fate in the EV era. Passion or progress — can Ferrari have both?

McDonald’s is feeling the heat — U.S. sales are sliding, analysts are turning bearish, and even Ozempic might be eating into demand. In this episode of Implied, we break down why traffic is dipping, how the $5 Meal Deal and Monopoly promo could spark a rebound, and whether 48 straight years of dividend hikes can keep investors loyal. The world’s biggest fast-food chain isn’t broken… but it’s definitely being tested.